Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming.

Researchers have developed the downstream section of a new streamlined production method for an emerging virus class.

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042. The company issued $4m in ordinary shares and additionally agreed ...

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...

Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II breast cancer trial. The US-based company noted that its ...

Biotech Theriva puts GvHD drug on back burner to focus on oncolytic adenovirus By Ben Adams Mar 7, 2025 4:47am graft vs. host disease oncolytic virus Biotech ...

UroGen is paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged BCG therapy.

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

Oncolytic virus (OV)-based immunotherapy leverages the natural or genetically modified abilities of viruses to selectively infect and destroy cancer cells while stimulating the immune system's ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues ...